Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
83.94
+0.04 (+0.05%)
Official Closing Price
Updated: 4:15 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
34
35
Next >
Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron
February 11, 2022
Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) has demonstrated in vitro activity against ten SARS-CoV-2 variants, including omicron. The...
Via
Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
February 11, 2022
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.
Via
Investor's Business Daily
The 7 Highest Dividend Stocks for Income Investors
February 09, 2022
These dividend stocks, including SCCO stock and CQP stock, offer high yields, a proven track record and high ratings in Dividend Grader.
Via
InvestorPlace
Glaxo's Q4 Pharma Sales Jump 20% Boosted By COVID-19 Treatment; Prepares For Spin-Off
February 09, 2022
GlaxoSmithKline Plc's (NYSE: GSK) turnover was
Via
Benzinga
RedHill Biopharma's COVID-19 Antiviral Cuts Mortality By 70% In Remdesivir Treated Patients
February 07, 2022
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced results from two recently completed prespecified analyses from the oral opaganib Phase 2/3 study in hospitalized severe COVID-19.
Via
Benzinga
Gilead Sciences: Q4 Earnings Insights
February 01, 2022
Gilead Sciences (NASDAQ:GILD) reported its Q4 earnings results on Tuesday, February 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Gilead to Report Q4 Earnings: Is a Beat in the Cards?
January 29, 2022
Biotech major Gilead Sciences Inc.is slated to report fourth-quarter 2021 results on Feb 1, after market close.
Via
Talk Markets
What 5 Analyst Ratings Have To Say About Gilead Sciences
January 28, 2022
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings:
Via
Benzinga
Why Jim Cramer Believes Loves Berkshire Hathaway And Rivian
February 07, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is not a fan of Gilead Sciences, Inc. (NASDAQ: GILD). "They have what I call big hat, no cattle, and I like ones that have cattle," he added.
Via
Benzinga
5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet
February 04, 2022
Joe Biden is redoubling his efforts to fight cancer with a new "cancer cabinet." Here are the biotech stocks to buy that can benefit.
Via
InvestorPlace
GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead
February 02, 2022
GlaxoSmithKline plc (NYSE: GSK) has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc (NASDAQ: GILD).
Via
Benzinga
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings
January 26, 2022
The
Via
Benzinga
Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates
February 02, 2022
Gilead Sciences Inc (NASDAQ: GILD) posted
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 01, 2022
Gainers Epizyme (NASDAQ:EPZM) shares incr...
Via
Benzinga
Gilead Stock Dives After Two Major Charges Dig Into Fourth-Quarter Earnings
February 01, 2022
Gilead shares toppled after hours on lighter-than-expected fourth-quarter profit.
Via
Investor's Business Daily
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 31, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Will Moderna Sidestep The Looming Sales Cliff After FDA Approves Covid Shot?
January 31, 2022
Currently, analysts expect Moderna sales to drop off after 2022.
Via
Investor's Business Daily
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Via
Benzinga
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
January 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way
January 25, 2022
Sierra Oncology spent just $3 million up front to acquire momelotinib.
Via
Investor's Business Daily
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
January 24, 2022
Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
January 24, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results...
Via
Benzinga
FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression
January 24, 2022
The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) for non-hospitalized adult and adolescent patients at high risk of progression to...
Via
Benzinga
Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
January 20, 2022
Key Takeaways Everest has signed a global licensing deal for an anti-viral Covid treatment being developed by Singapore’s Experimental Drug Development Centre Similar oral...
Via
Benzinga
Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs
January 19, 2022
Gilead Sciences Inc (NASDAQ: GILD) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV...
Via
Benzinga
Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US
January 18, 2022
Gilead Sciences Inc (NASDAQ: GILD) recently notified the FDA of its decision to voluntarily withdraw the use of Zydelig for two types of blood cancer, including...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 12, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...
Via
Benzinga
7 Safe Stocks for Your Retirement
January 07, 2022
In a dynamic market like the one we're in now, it's important to buy safe stocks that will build your nest egg in the years to come.
Via
InvestorPlace
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.